Implantica (IMP) Q2 2026 earnings summary

Executive summary

• Achieved FDA approval for RefluxStop®, enabling entry into the U.S., the largest global market for medical devices, and supporting a major commercial launch.

• Net sales grew 66% year-over-year in Q2 2026, reaching EUR 717,000, driven by expanding adoption in Europe and U.S. launch preparations.

• Five-year clinical data and endorsements from leading health authorities support rapid adoption and market expansion.

• Strategic expansion in Europe continues, with over 60 Centers of Excellence and strong growth in Italy, Spain, Switzerland, and the UK.

• Expansion plans underway for Canada, Japan, Middle East, and other regions leveraging U.S. approval.

Financial highlights

• Q2 2026 net sales reached EUR 717,000, up 66% year-over-year; H1 2026 net sales were EUR 1.57 million, up 34% year-over-year.

• Adjusted gross margin improved to 94% in Q2 2026, up from 90% in Q2 2025.

• Operating loss for Q2 2026 was EUR 4.2 million, a 7% improvement year-over-year; H1 EBIT loss was EUR 8.06 million.

• Operating cash outflow was EUR 3.9 million in Q2 2026, stable year-over-year; cash and cash equivalents at quarter-end were EUR 41.7 million.

• No interest-bearing debt as of June 30, 2026.

Outlook and guidance

• U.S. launch to proceed stepwise, starting with 4–10 proctor centers and expanding to 5–10 major centers in the first year.

• Accelerated U.S. launch planned, leveraging five-year clinical and health economic data.

• Expansion in Europe expected to continue, with increased reimbursement and adoption in Italy, Germany, Spain, Switzerland, and the UK.

• Capital Markets Day scheduled for September 9 to provide detailed financial roadmap and U.S. launch milestones.

• Long-term revenue potential in the U.S. estimated at up to $2.5 billion with 1% market penetration.